Not yet recruiting
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
NCT06746961
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
- Locations
-
Not specified